



Cornea Update (04/30/22 @ 8 a.m. ET)

Saturday, April 30, 2022

Wills Eye Auditorium

Conference Description:

[Click Here to Sign Up for the Livestream](#)

Wills Eye Hospital is re-opening Saturday Updates to a limited number of guests to attend in-person.

If you would like to attend in-person, please select the in-person option when registering for the event.

This conference focuses on an in-depth update on the care of patients with Herpes Simplex and Varicella Zoster viral corneal disease. Topics will include the use of antivirals and steroids in viral keratitis, considerations before operating on patients with a history of viral disease, medications in the pipeline for treatment, and the long term management of sequelae including antiviral prophylaxis, neurotrophic keratitis, neovascularization, and corneal neuralgia after viral keratitis. Lectures will be focused and directed with opportunity for panel discussion to incorporate audience questions.

At the conclusion of the course, participants should be able to:

- 1 Discuss important new advances in the etiologies, diagnosis, and treatment/prevention of eye diseases.
- 2 Identify basic and clinical vision research that can be transformed into improved clinical care.
- 3 Assess the role of new technologies in the evaluation and treatment of eye diseases.
- 4 Describe factors that impact the effective delivery of the highest quality eye care for the public.
- 5 Identify clinical, scientific, and ethical issues confronting the profession.
- 6 Obtain information and tools through multiple facets to help ophthalmologists deliver high and efficient quality of care.

Accreditation Statement:

The Wills Eye Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Wills Eye Hospital designates this live educational activity for a maximum of 4.00 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement:

It is the policy of Wills Eye Hospital that the information presented at Wills Eye Hospital's CME activities will be commercially unbiased and based on scientific and clinical evidence. To help participants make judgments about the presence of commercial bias, Wills Eye Hospital provides information that planners and speakers have disclosed about financial relationships they have with commercial entities that produce, market, re-sell, or distribute health care goods or services consumed by, or used on, patients. All relevant financial relationships have been mitigated.

Name of individual	Individual's role in activity	Name of Ineligible Company(s) / Nature of Relationship(s)
Brandon D. Ayres, MD	Faculty	Consulting Fee-Alcon Consulting Fee-Allergan Consulting Fee-Bausch + Lomb Consulting Fee-Sun Pharmaceutical Industries Consulting Fee-Novartis Consulting Fee-Carl Zeiss Consulting Fee-Omeros Consulting Fee-Dompé - 10/01/2021
Christopher Barron, MD	Faculty	Nothing to disclose - 02/01/2022
Brenton D. Finklea, MD	Faculty	Nothing to disclose - 10/01/2021
Joanne S Francis, MD	Faculty	Nothing to disclose - 12/05/2021
Samantha Habhab, MD	Faculty	Nothing to disclose - 12/05/2021
Kristin M. Hammersmith, MD	Faculty	Nothing to disclose - 10/01/2021
Sadeer B. Hannush, MD	Faculty	Nothing to disclose - 10/06/2021
Aditya Kanesa-thasan, MD	Faculty	Nothing to disclose - 09/29/2021
Parveen K. Nagra, MD	Faculty	Nothing to disclose - 09/29/2021
Irving M. Raber, MD	Faculty	Nothing to disclose - 09/28/2021
Zeba A. Syed, MD	Faculty	Speakers Bureau-Bio-Tissue Grant or research support-Dompé - 09/27/2021
Christopher J. Rapuano, MD	Faculty, Planner	Consulting Fee-Bio-Tissue-Relationship_has_not_ended Consulting Fee-Dompé - Relationship_has_not_ended Consulting Fee-Glaukos Corporation-Relationship_has_not_ended Consulting Fee-Oyster Point Pharmaceuticals-Relationship_has_not_ended Consulting Fee-Sun Pharmaceutical Industries-Relationship_has_not_ended Consulting Fee-TearLab-Relationship_has_not_ended Honoraria-Dompé -Relationship_has_not_ended - 02/16/2022
Ralph C. Eagle Jr., MD	Other Planning Committee Member	Stocks or stock options, excluding diversified mutual funds-Merck - 01/15/2022

